| 17.03 0 (0%) | 09-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 20.02 |
1-year : | 20.15 |
| Resists | First : | 17.14 |
Second : | 17.25 |
| Pivot price | 17.03  |
|||
| Supports | First : | 16.95 |
Second : | 14.11 |
| MAs | MA(5) : | 17.03 |
MA(20) : | 17.04 |
| MA(100) : | 16.8 |
MA(250) : | 16.92 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 11.7 | D(3) : | 12.6 |
| RSI | RSI(14): 53.2 | |||
| 52-week | High : | 21.03 | Low : | 13.07 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TBPH ] has closed above bottom band by 39.6%. Bollinger Bands are 88.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 60 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 17.05 - 17.13 | 17.13 - 17.2 |
| Low: | 16.83 - 16.93 | 16.93 - 17.01 |
| Close: | 16.89 - 17.04 | 17.04 - 17.16 |
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Thu, 24 Sep 2026
Theravance Biopharma CEO's 1.38M shares canceled | TBPH Insider Trading - Stock Titan
Wed, 23 Sep 2026
Theravance Biopharma Announced Transfer or Voluntary Withdrawal of Listing - TradingView
Wed, 23 Sep 2026
Theravance Biopharma to Be Acquired by Zymeworks for $17 Per Share Plus CVR - TradingView
Mon, 10 Aug 2026
Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update - PR Newswire
Wed, 01 Jul 2026
Here’s Why Zymeworks Inc. Paid $929M For Theravance Biopharma (NASDAQ:ZYME) - Seeking Alpha
Tue, 30 Jun 2026
Theravance Stock Down 3% After Zymeworks Announces Buyout - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 52 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 4.6 (%) |
| Held by Institutions | 94.7 (%) |
| Shares Short | 1,690 (K) |
| Shares Short P.Month | 1,710 (K) |
| EPS | 1.03 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.57 |
| Profit Margin | 51.5 % |
| Operating Margin | 8.8 % |
| Return on Assets (ttm) | 1.3 % |
| Return on Equity (ttm) | 20.9 % |
| Qtrly Rev. Growth | -20.9 % |
| Gross Profit (p.s.) | 1.5 |
| Sales Per Share | 2 |
| EBITDA (p.s.) | 0.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 54 (M) |
| Levered Free Cash Flow | 5 (M) |
| PE Ratio | 16.37 |
| PEG Ratio | 0 |
| Price to Book value | 3.05 |
| Price to Sales | 8.47 |
| Price to Cash Flow | 16.45 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|